NewLink Genetics (NLNK) Tops Q4 EPS by 16c

NewLink Genetics (NASDAQ: NLNK) reported Q4 EPS of ($0.46), $0.16 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $4.46 million.

NewLink Genetics ended the year on December 31, 2016, with cash, cash equivalents, and certificates of deposit totaling $131.5 million compared to $197.8 million for the year ending December 31, 2015. The Company’s cash position is sufficient to fund current operations in the near and medium term.

For earnings history and earnings-related data on NewLink Genetics (NLNK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c